NCT00730236View on ClinicalTrials.gov

A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

PHASE3CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

October 31, 2011

Conditions
Homozygous Familial Hypercholesterolemia
Interventions
DRUG

AEGR-733

5-80 mg daily by mouth for 1.5 yrs

Trial Locations (10)

7925

University of Capetown, Cape Town

9300

Cardiology Research, Bloemfontein

19104

University of Pennsylvania, Philadelphia

90048

Cedars-Sinai Medical Center, Los Angeles

N6A 5K8

Robarts Research Institute, London

G7H 5H6

Lipid Clinic and University of Montreal Community Genomic Medicine Center, Chicoutimi

Unknown

Dipartimento di Medicina Clinica e Della Patalogie Emergenti, Palermo

Medicina Interna Universitaria, Ferrara

Centro Universitario Dislipidemie, Milan

Dipartimento di Clinica e Terapia Medica, Roma

Sponsors
All Listed Sponsors
collaborator

FDA Office of Orphan Products Development

FED

lead

Aegerion Pharmaceuticals, Inc.

INDUSTRY

NCT00730236 - A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) | Biotech Hunter | Biotech Hunter